ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • View Item
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Achieving hidradenitis suppurativa response score is associated with significant improvement in clinical and patient-reported outcomes: Post hoc analysis of pooled data from PIONEER I and II

Permanent link
https://hdl.handle.net/10037/14901
DOI
https://doi.org/10.2340/00015555-3012
Thumbnail
View/Open
article.pdf (431.3Kb)
Publisher's version (PDF)
Date
2018-08-07
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Kimball, Alexandra Boer; Tzellos, Thrasyvoulos; Calimlim, Brian M; Teixeira, Henrique D; Geng, Ziqian; Okun, Martin M
Abstract
Hidradenitis Suppurativa Clinical Response (HiSCR), is a validated tool that has been used to assess the efficacy of adalimumab among patients with hidradenitis suppurativa. We evaluated the clinical meaning of HiSCR by relating it to patient-reported outcomes to give further context to its achievement in a post hoc analysis of integrated data from two phase 3 clinical trials (PIONEER I and II). Pooling placebo and active treatment arms, 39% of patients (245/629) achieved HiSCR at week 12. Irrespective of treatment, significantly (p < 0.05) more HiSCR responders than non-responders experienced clinically meaningful improvement in Dermatology Life Quality Index (60.5% vs 30.4%), Pain Numeric Rating Scale (46.9% vs 19.9%), hidradenitis suppurativa quality of life (49.4% vs 26.9%), work-related performance (52.6% vs 37.7%), and non-work-related performance (59.5% vs 33.3%). Clinically meaningful outcomes in hidradenitis suppurativa are more likely to be attained in patients achieving HiSCR level improvement.
Description
Source at https://doi.org/10.2340/00015555-3012.
Publisher
Society for Publication of Acta Dermato-Venereologica
Citation
Kimball, A.B., Tzellos, T., Calimlim, B.M., Teixeira, H.D., Geng, Z. & Okun, M.M. (2018). Achieving hidradenitis suppurativa response score is associated with significant improvement in clinical and patient-reported outcomes: Post hoc analysis of pooled data from PIONEER I and II. Acta Dermato-Venereologica, 98(10), 932-937. https://doi.org/10.2340/00015555-3012
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (klinisk medisin) [1974]

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)